BDF Gestion Acquires New Shares in Humana Inc. (NYSE:HUM)

BDF Gestion acquired a new stake in shares of Humana Inc. (NYSE:HUM) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 11,618 shares of the insurance provider’s stock, valued at approximately $2,948,000.

Other institutional investors also recently modified their holdings of the company. FNY Investment Advisers LLC grew its stake in shares of Humana by 6,647.5% during the 4th quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock valued at $6,916,000 after purchasing an additional 26,856 shares during the period. PDT Partners LLC grew its stake in shares of Humana by 190.0% during the 3rd quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock valued at $1,286,000 after purchasing an additional 2,660 shares during the period. Secure Asset Management LLC bought a new stake in shares of Humana during the 4th quarter valued at about $244,000. Ontario Teachers Pension Plan Board grew its stake in shares of Humana by 6.5% during the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider’s stock valued at $371,705,000 after purchasing an additional 71,910 shares during the period. Finally, Swedbank AB grew its stake in shares of Humana by 3.0% during the 3rd quarter. Swedbank AB now owns 105,976 shares of the insurance provider’s stock valued at $33,567,000 after purchasing an additional 3,085 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HUM has been the topic of a number of analyst reports. UBS Group lowered their price objective on Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research report on Friday, October 4th. Royal Bank of Canada lowered their price objective on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Morgan Stanley lifted their price objective on Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Deutsche Bank Aktiengesellschaft lowered their price objective on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a research report on Thursday, October 3rd. Finally, Sanford C. Bernstein raised Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price target on the stock in a report on Tuesday, October 8th. Nineteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $297.68.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.32% of the stock is currently owned by company insiders.

Humana Trading Down 2.9 %

Shares of NYSE HUM opened at $294.18 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market capitalization of $35.42 billion, a P/E ratio of 26.06, a price-to-earnings-growth ratio of 2.15 and a beta of 0.55. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The business has a fifty day moving average price of $275.44 and a 200 day moving average price of $303.14.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The company had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. Equities research analysts expect that Humana Inc. will post 16.11 EPS for the current fiscal year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.